Oestrogen and progesterone receptor status of individual foci in multifocal invasive ductal breast cancer

Figures & data

Table I.  Allred immunohistochemical scoring system [8]. The score for heterogeneity (proportion of nuclei staining) is added to the score for staining intensity to give a value of 0–8. A value of 3 or more represents a positive result.

Score for proportion	Score for intensity
0 = No staining	0 = No staining
1 = < 1% nuclei staining	1 = weak staining
2 = 1–10% nuclei staining	2 = moderate staining
3 = 11–33% nuclei staining	3 = strong staining
4 = 34–66% nuclei staining
5 = 67–100% nuclei staining

Table II.  Clinical details of tumour foci from 18 patients with MFBC. The immunohistochemical score for ER and PR was assigned according to Table I.

Patient #	Tumour Focus #	Size (mm)	Grade	ER status (score)	PR status (score)
1	A5	23	2	+ (7)	+ (6)
	A9	4	2	+ (7)	+ (7)
	B4	3	2	+ (7)	+ (6)
2	A2	18	1	+ (7)	+ (7)
	A14	<5	1	+ (7)	+ (7)
	A20	<5	1	+ (7)	+ (8)
	A23	<5	1	+ (7)	+ (7)
3	A5	12	2	+ (4)	Neg (0)
	A12	7	2	+ (8)	+ (6)
	A9	6	2	+ (8)	+ (6)
	A8	5	2	+ (7)	+ (7)
4	A10	12	2	+ (5)	+ (8)
	A14	4	2	+ (5)	+ (5)
	A16	3	2	+ (7)	Neg (2)
5	A4	12.5	3	+ (7)	+ (7)
	A6	2	1	+ (7)	+ (7)
6	A5	24	2	+ (5)	+ (5)
	A10	13	2	+ (4)	+ (5)
7	A5	8	1	+ (7)	+ (8)
	A	N/A	2	+ (8)	+ (8)
8	A13a	22	3	Neg (0)	Neg (0)
	A13b	10	3	Neg (0)	Neg (0)
	A9	6	3	Neg (0)	Neg (0)
	A8	6	3	Neg (0)	Neg (0)
9	B3	17	3	+ (7)	+ (7)
	B4	5	3	+ (5)	+ (7)
	B5	5	3	+ (7)	+ (7)
	B7	5	3	+ (7)	+ (7)
	A4*	14	3	Neg (0)	Neg (0)
10	A3	17	3	Neg (0)	Neg (0)
	A3	5	3	Neg (0)	Neg (0)
11	A12	12	2	+ (7)	+ (7)
	A24	10	2	+ (7)	+ (7)
12	A7	26.5	2	+ (5)	+ (5)
	B5	8	1	+ (7)	+ (7)
13	A3	16	1	+ (8)	+ (8)
	A3	12	1	+ (8)	+ (8)
14	A7	25	2	+ (7)	+ (7)
	A12	6	2	+ (7)	+ (8)
15	A6	24	2	+ (6)	+ (7)
	B3	3	2	+ (7)	+ (3)
16	A1	30	2	+ (7)	+ (5)
	A3	2	2	+ (7)	+ (6)
	A8	2	2	+ (7)	+ (3)
17	A11	24	2	+ (5)	Neg (2)
	A11	3	2	+ (5)	Neg (2)
18	A4	8	1	+ (4)	+ (8)
	A4	8	1	+ (4)	+ (8)

*Contralateral tumour

Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474–81

 PubMed Web of Science ®Google Scholar